Infinity and MedImmune Announce Approval for Generic Name for Novel Hsp90 Inhibitor

Feb. 4, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary or generic name "retaspimycin" for the companies' lead heat shock protein 90 (Hsp90) inhibitor, IPI-504. Retaspimycin hydrochloride is currently being evaluated in clinical trials for the potential treatment of a variety of solid tumor cancers, including gastrointestinal stromal tumors, non-small cell lung cancer, and hormone resistant prostate cancer.